Featured Publications
Enhancing peptide ligand binding to vascular endothelial growth factor by covalent bond formation.
Marquez BV, Beck HE, Aweda TA, Phinney B, Holsclaw C, Jewell W, Tran D, Day JJ, Peiris MN, Nwosu C, Lebrilla C, Meares CF. Enhancing peptide ligand binding to vascular endothelial growth factor by covalent bond formation. Bioconjugate Chemistry 2012, 23: 1080-9. PMID: 22537066, PMCID: PMC3431436, DOI: 10.1021/bc300114d.Peer-Reviewed Original ResearchDevelopment of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor.
Marquez BV, Ikotun OF, Parry JJ, Rogers BE, Meares CF, Lapi SE. Development of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2014, 55: 1029-34. PMID: 24732153, DOI: 10.2967/jnumed.113.130898.Peer-Reviewed Original Research[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer
Laforest R, Lapi SE, Oyama R, Bose R, Tabchy A, Marquez-Nostra BV, Burkemper J, Wright BD, Frye J, Frye S, Siegel BA, Dehdashti F. [89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. Molecular Imaging And Biology 2016, 18: 952-959. PMID: 27146421, PMCID: PMC5096950, DOI: 10.1007/s11307-016-0951-z.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerDose-limiting organPositron emission tomographyBreast cancerMSv/MBqOptimal imaging timeHuman radiation dosimetryPET/CT imagesOrgan time activity curvesGreater tumorTime-activity curvesPurposeThe purposeHuman dosimetryEmission tomographyBiodistribution dataEffective dosePatientsAdverse effectsCancerLiverImaging parametersWomenPresent studyTomographyDaysDevelopment of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer
Cavaliere A, Sun S, Lee S, Bodner J, Li Z, Huang Y, Moores SL, Marquez-Nostra B. Development of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 48: 383-394. PMID: 32770372, PMCID: PMC7855369, DOI: 10.1007/s00259-020-04978-6.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerEpidermal growth factor receptorPET/CTMDA-MB-468MDA-MB-231C-MetGrowth factor receptorIsotype controlBreast cancerMDA-MB-468 xenograftsBispecific antibodiesC-Met expression levelsHCC827 lung cancer cellsMono-targeted therapiesFactor receptorLevels of EGFROptimal imaging time pointC-Met expressionNovel bispecific antibodyStandard uptake valueRadioligand binding studiesExpression levelsLung cancer cellsMDA-MB-453Imaging time point[89Zr]ZrDFO-CR011 positron emission tomography correlates with response to glycoprotein non-metastatic melanoma B-targeted therapy in triple negative breast cancer
Lee S, Cavaliere A, Gallezot JD, Keler T, Michelhaugh SK, Belitzky E, Liu M, Mulnix T, Maher SE, Bothwell ALM, Li F, Phadke M, Mittal S, Marquez-Nostra B. [89Zr]ZrDFO-CR011 positron emission tomography correlates with response to glycoprotein non-metastatic melanoma B-targeted therapy in triple negative breast cancer. Molecular Cancer Therapeutics 2022, 21: molcanther.0590.2021. PMID: 35027482, PMCID: PMC8898259, DOI: 10.1158/1535-7163.mct-21-0590.Peer-Reviewed Original ResearchConceptsStandardized uptake valueTriple-negative breast cancerWeeks of treatmentCDX-011Tumor modelBreast cancerMelanoma BPretreatment standardized uptake valueAntibody-drug conjugate (ADC) therapyPatient-derived tumor modelsNegative breast cancerSingle bolus injectionPositron emission tomographyTumor regrewPretreatment PETADC therapyPrognostic markerBolus injectionTumor volumeSUV ratioRadiotracer uptakeUptake valueStrong inverse correlationTumor typesPercent change
2024
Nuclear Imaging of Bispecific Antibodies on the Rise
Roohani B, Mendez A, Dangarwala M, Katz S, Marquez-Nostra B. Nuclear Imaging of Bispecific Antibodies on the Rise. Journal Of Nuclear Medicine 2024, 65: 1512-1517. PMID: 39266295, PMCID: PMC11448611, DOI: 10.2967/jnumed.123.267215.Peer-Reviewed Original ResearchPilot PET study of vaginally administered bioadhesive nanoparticles in cynomolgus monkeys: Kinetics and safety evaluation
Grun M, Honhar P, Wang Y, Rossano S, Khang M, Suh H, Fowles K, Kliman H, Cavaliere A, Carson R, Marquez‐Nostra B, Saltzman W. Pilot PET study of vaginally administered bioadhesive nanoparticles in cynomolgus monkeys: Kinetics and safety evaluation. Bioengineering & Translational Medicine 2024 DOI: 10.1002/btm2.10661.Peer-Reviewed Original ResearchVaginal dosage formsBioadhesive nanoparticlesCynomolgus monkeysAnalysis of inflammatory biomarkersVaginal microbicidesVaginal canalMultiple dosesInflammatory biomarkersTherapeutic efficacyVaginal fluidSystemic circulationLong-term deliveryNoninvasive imagingClinical translationDosage formsNon-human primatesDelivery vehiclesMonkeysDeliveryVaginitisUterusMicrobicidesSafety evaluationBiodistributionDoseMelanocortin-1 Receptor Expression as a Marker of Progression in Melanoma
Su D, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L, Kluger H. Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma. JCO Precision Oncology 2024, 8: e2300702. PMID: 38662983, PMCID: PMC11513442, DOI: 10.1200/po.23.00702.Peer-Reviewed Original ResearchConceptsMC1R expressionMelanoma progressionAssociated with shorter survivalStages of melanoma progressionCases of benign neviChronic sun exposureMarkers of progressionHuman melanoma tissuesBreslow thicknessMelanocortin-1Metastatic melanomaOverall survivalPrimary melanomaMetastatic tumorsMelanoma cohortReceptor expressionPredictive biomarkersAggressive melanomaPrimary lesionTissue microarrayShorter survivalMale sexQuantitative immunofluorescenceBenign neviClinical trials
2023
P-184 Investigation of cell surface murine CD68 as a pan-macrophage biomarker by immunoSPECT and optical imaging
Roohani B, Katz S, Belitzky E, Cavaliere A, Lee S, Rajabimoghadam K, Liu M, Sinusas A, Kluger H, Marquez-Nostra B. P-184 Investigation of cell surface murine CD68 as a pan-macrophage biomarker by immunoSPECT and optical imaging. Nuclear Medicine And Biology 2023, 126: 108651. DOI: 10.1016/j.nucmedbio.2023.108651.Peer-Reviewed Original Research
2022
Determining Binding Affinity (KD) of Radiolabeled Antibodies to Immobilized Antigens.
Belitzky E, Cavaliere A, Rajabimoghadam K, Marquez-Nostra B. Determining Binding Affinity (KD) of Radiolabeled Antibodies to Immobilized Antigens. Journal Of Visualized Experiments 2022 PMID: 35815982, DOI: 10.3791/63927.Peer-Reviewed Original ResearchPET Imaging in Animal Models of Alzheimer’s Disease
Chen B, Marquez-Nostra B, Belitzky E, Toyonaga T, Tong J, Huang Y, Cai Z. PET Imaging in Animal Models of Alzheimer’s Disease. Frontiers In Neuroscience 2022, 16: 872509. PMID: 35685772, PMCID: PMC9171374, DOI: 10.3389/fnins.2022.872509.Peer-Reviewed Original ResearchAnimal modelsPreclinical PET imagingPET imagingOngoing clinical trialsΒ-amyloid plaquesAnimal model developmentPathogenesis/progressionTau-PETClinical trialsTau tanglesTherapeutic effectAD modelNovel treatmentsAlzheimer's diseaseDrug action mechanismsDiseaseAction mechanismImagingPatientsPETPlaquesProgressionTrialsAntemortemP-303 Synthesis and preclinical evaluation of PD-L1 PET tracer [18F]FDHPA in mice
Tong J, Chen B, Alluri S, Gu J, Zheng M, Zheng C, Felchner Z, Gao H, Zhang L, Kapinos M, Labaree D, Ropchan J, Nabulsi N, Marquez-Nostra B, Carson R, Huang Y, Cai Z. P-303 Synthesis and preclinical evaluation of PD-L1 PET tracer [18F]FDHPA in mice. Nuclear Medicine And Biology 2022, 108: s214. DOI: 10.1016/s0969-8051(22)00439-5.Peer-Reviewed Original ResearchClinical Evaluation of Nuclear Imaging Agents in Breast Cancer
Li Z, Aboian MS, Zhu X, Marquez-Nostra B. Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer. Cancers 2022, 14: 2103. PMID: 35565232, PMCID: PMC9101155, DOI: 10.3390/cancers14092103.Peer-Reviewed Original ResearchPositron emission tomographyBreast cancerMolecular profilingTherapeutic targetSingle photon emission tomography (SPECT) imagingSelection of patientsNuclear imaging agentCustomization of therapyPrecision medicineImaging agentEmission Tomography ImagingMetastatic diseaseClinical evaluationClinical studiesClinical practiceClinical decisionEmission tomographyClinical researchStudy designCancerTomography imagingTherapyDifferent receptorsNoninvasive imagingSPECT agent
2021
Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer
Fang H, Cavaliere A, Li Z, Huang Y, Marquez-Nostra B. Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer. Frontiers In Pharmacology 2021, 12: 627693. PMID: 33986665, PMCID: PMC8111013, DOI: 10.3389/fphar.2021.627693.Peer-Reviewed Original ResearchDifferent molecular subtypesBreast cancerPositron emission tomographyMolecular subtypesEmission tomographySingle photon emission tomographyBreast cancer patientsResponse of therapyBreast cancer therapyNew therapeutic agentsPreclinical advancesMolecular imaging methodsCancer patientsCare treatmentCommon cancerPreclinical studiesTherapeutic strategiesCancerDrug resistanceTherapeutic agentsTherapyNew targetsCancer therapyPrecision medicinePatients
2019
The Radiopharmaceutical Chemistry of Zirconium-89
Marquez-Nostra B, Viola N. The Radiopharmaceutical Chemistry of Zirconium-89. 2019, 371-390. DOI: 10.1007/978-3-319-98947-1_21.Peer-Reviewed Original ResearchZirconium-89Radiopharmaceutical chemistryPositron emission tomography (PET) probesStable coordinationDFO complexBiomedical applicationsChemical propertiesNew chelatorsStable chelatorsPositron-emitting radionuclidesVivo stabilityRadiochemistryNon-specific accumulationRecent progressChelatorsVivo releaseDevelopment of alternativesChemistryOnly chelatorComplexesTomography probeStabilityDesferrioxamineCoordinationGeneral overviewImaging of HER2 with [89Zr]pertuzumab in Response to T-DM1 Therapy
Massicano AVF, Lee S, Crenshaw BK, Aweda TA, Sayed R, Super I, Bose R, Marquez-Nostra BV, Lapi SE. Imaging of HER2 with [89Zr]pertuzumab in Response to T-DM1 Therapy. Cancer Biotherapy & Radiopharmaceuticals 2019, 34: 209-217. PMID: 30676778, PMCID: PMC7227434, DOI: 10.1089/cbr.2018.2654.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAnimalsAntibodies, Monoclonal, HumanizedBreast NeoplasmsCell Line, TumorDeferoxamineFemaleHumansIsothiocyanatesMaytansineMiceMice, NudePositron Emission Tomography Computed TomographyRadioisotopesRadiopharmaceuticalsReceptor, ErbB-2TrastuzumabTreatment OutcomeTumor BurdenXenograft Model Antitumor AssaysX-Ray MicrotomographyZirconiumConceptsT-DM1 therapyBreast cancerTumor volumeHuman epidermal growth factor receptor 2HER2-positive breast cancerEpidermal growth factor receptor 2BT-474 tumorsGrowth factor receptor 2HER2-positive tumorsFactor receptor 2HER2 expressionBCa patientsReceptor 2TherapyTumorsEarly responseBetter delineationPertuzumabPoor delineationMBq/MiceTreatmentResponsePatientsHER2
2018
Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer
Dehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, Diebolder P, Mpoy C, Rogers BE, Lapi SE, Laforest R, Siegel BA. Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. Breast Cancer Research And Treatment 2018, 169: 523-530. PMID: 29442264, PMCID: PMC5955803, DOI: 10.1007/s10549-018-4696-z.Peer-Reviewed Original ResearchAdultAgedBiomarkers, TumorBiopsyBreast NeoplasmsFemaleHumansImage Processing, Computer-AssistedMiddle AgedMultimodal ImagingNeoplasm GradingNeoplasm StagingPositron Emission Tomography Computed TomographyRadioisotopesRadiopharmaceuticalsReceptor, ErbB-2ROC CurveSensitivity and SpecificityTrastuzumabZirconiumEvaluation of Next-Generation Anti-CD20 Antibodies Labeled with 89Zr in Human Lymphoma Xenografts
Yoon JT, Longtine MS, Marquez-Nostra BV, Wahl RL. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with 89Zr in Human Lymphoma Xenografts. Journal Of Nuclear Medicine 2018, 59: 1219-1224. PMID: 29348316, PMCID: PMC6071500, DOI: 10.2967/jnumed.117.203299.Peer-Reviewed Original ResearchConceptsTumor uptakeCD20 antibodyLymphoma xenograftsMonoclonal antibodiesDrug AdministrationBurkitt's lymphoma xenograftsHigher splenic uptakeAnti-CD20 antibodyCD20 monoclonal antibodyPET/CT imagingHuman lymphoma xenograftsSmall-animal PET/CT imagesPreclinical mouse modelsB-cell lymphomaPET/CTPET/CT imagesHigh tumor uptakeNext-Generation AntiClear tumor uptakePalpable tumorsSplenic uptakeImmunodeficient miceEffective treatmentMouse modelObinutuzumabTargeting HER2 in Nuclear Medicine for Imaging and Therapy
Massicano AVF, Marquez-Nostra BV, Lapi SE. Targeting HER2 in Nuclear Medicine for Imaging and Therapy. Molecular Imaging 2018, 17: 1536012117745386. PMID: 29357745, PMCID: PMC5784567, DOI: 10.1177/1536012117745386.BooksConceptsHuman epidermal growth factor 2HER2 expressionHER2 statusEpidermal growth factor 2Treatment of patientsHER2-positive cancersWhole-body assessmentStandard diagnostic techniquesMetastatic settingGrowth factor 2Breast cancerClinical studiesNuclear medicineTumor fociInvasive biopsyAlternative treatmentTime of analysisSmall sample sizeTherapyNuclear imagingBiopsyPatientsFactor 2TumorsCancer
2017
Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent
Marquez-Nostra BV, Lee S, Laforest R, Vitale L, Nie X, Hyrc K, Keler T, Hawthorne T, Hoog J, Li S, Dehdashti F, X. C, Lapi SE. Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent. Oncotarget 2017, 5: 104303-104314. PMID: 29262642, PMCID: PMC5732808, DOI: 10.18632/oncotarget.22228.Peer-Reviewed Original ResearchTriple-negative breast cancerMDA-MB-468 xenograftsNegative breast cancerCDX-011Breast cancerMean SUVTumor uptakePatient-derived xenograft modelsDiagnostic imaging agentsGPNMB expressionMDA-MB-231 tumorsSelection of patientsTNBC cell linesImaging agentGlembatumumab vedotinPDX micePharmacologic propertiesPreclinical studiesXenograft modelTargeted treatmentMelanoma BDays p.Preclinical PET imagingUptake correlatesEffective dose